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BACKGROUND: Opioid-related adverse events are a serious problem in hospitalized patients. 
Little is known about patients who are likely to experience opioid-induced respiratory depression 
events on the general care floor and may benefit from improved monitoring and early intervention. 
The trial objective was to derive and validate a risk prediction tool for respiratory depression in 
patients receiving opioids, as detected by continuous pulse oximetry and capnography monitoring.
METHODS: PRediction of Opioid-induced respiratory Depression In patients monitored by cap-
noGraphY (PRODIGY) was a prospective, observational trial of blinded continuous capnography 
and oximetry conducted at 16 sites in the United States, Europe, and Asia. Vital signs were 
intermittently monitored per standard of care. A total of 1335 patients receiving parenteral 
opioids and continuously monitored on the general care floor were included in the analysis. A 
respiratory depression episode was defined as respiratory rate ≤5 breaths/min (bpm), oxygen 
saturation ≤85%, or end-tidal carbon dioxide ≤15 or ≥60 mm Hg for ≥3 minutes; apnea episode 
lasting >30 seconds; or any respiratory opioid-related adverse event. A risk prediction tool was 
derived using a multivariable logistic regression model of 46 a priori defined risk factors with 
stepwise selection and was internally validated by bootstrapping.
RESULTS: One or more respiratory depression episodes were detected in 614 (46%) of 1335 
general care floor patients (43% male; mean age, 58 ± 14 years) continuously monitored for 
a median of 24 hours (interquartile range [IQR], 17–26). A multivariable respiratory depres-
sion prediction model with area under the curve of 0.740 was developed using 5 independent 
variables: age ≥60 (in decades), sex, opioid naivety, sleep disorders, and chronic heart failure. 
The PRODIGY risk prediction tool showed significant separation between patients with and with-
out respiratory depression (P < .001) and an odds ratio of 6.07 (95% confidence interval [CI], 
4.44–8.30; P < .001) between the high- and low-risk groups. Compared to patients without 
respiratory depression episodes, mean hospital length of stay was 3 days longer in patients 
with ≥1 respiratory depression episode (10.5 ± 10.8 vs 7.7 ± 7.8 days; P < .0001) identified 
using continuous oximetry and capnography monitoring.
CONCLUSIONS: A PRODIGY risk prediction model, derived from continuous oximetry and capnog-
raphy, accurately predicts respiratory depression episodes in patients receiving opioids on the 
general care floor. Implementation of the PRODIGY score to determine the need for continuous 
monitoring may be a first step to reduce the incidence and consequences of respiratory compro-
mise in patients receiving opioids on the general care floor.  (Anesth Analg 2020;131:1012–24)
KEY POINTS
• Question: Can we use continuous capnography and oximetry monitoring data to derive a risk 
prediction tool to predict the risk of respiratory depression episodes in patients receiving 
parenteral opioid therapy on surgical and medical general care floors?
• Findings: The PRediction of Opioid-induced respiratory Depression In patients monitored by 
capnoGraphY (PRODIGY) trial found a 46% incidence of respiratory depression and developed 
a novel respiratory depression risk prediction tool, including 5 easy-to-assess variables: age 
≥60 years by decade, sex, opioid naivety, sleep disorders, and chronic heart failure.
• Meaning: This risk prediction tool, based on continuous, blinded oximetry and capnography 
data, accurately predicts respiratory depression in patients receiving parenteral opioids on the 
general care floor.
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GLOSSARY
ASA = American Society of Anesthesiologists; AUC = area under the curve; BMI = body mass 
index; bpm = breaths/min; CPAP = continuous positive airway pressure; Etco2 = end-tidal carbon 
dioxide; FAS = full analysis set; IPI = Integrated Pulmonary Index; IQR = interquartile range; IRB = 
institutional review board; MFAS = modified full analysis set; MME = morphine milligram equiva-
lent; OIRD = opioid-induced respiratory depression; OR = odds ratio; PRODIGY = PRediction of 
Opioid-induced respiratory Depression In patients monitored by capnoGraphY; Spo2 = oxygen satu-
ration; STOP = Snoring, Tiredness, Observed apnea, blood Pressure; STROBE = STrengthening the 
Reporting of OBservational studies in Epidemiology; STOP-BANG = Snoring, Tiredness, Observed 
apnea, blood Pressure, Body mass index, Age, Neck circumference, and Gender
The general care floor is a low-acuity inpatient environment. However, nearly half of all in-hospital cardiorespiratory events occur on the general care floor, often with catastrophic outcomes.
1,2 
A national registry identified 44,551 acute respiratory 
events in US hospitals, with an associated in-hospital 
mortality of nearly 40%.2 Early recognition of respi-
ratory compromise through continuous respiratory 
monitoring on the general care floor has been advo-
cated to reduce morbidity and mortality.3,4
Opioid-induced respiratory depression (OIRD) 
is one cause of respiratory compromise on the gen-
eral care floor, in part, because opioid administra-
tion remains common practice.5 OIRD is traditionally 
defined using surrogate measures, such as hypoven-
tilation with or without oxygen desaturation, and is 
often a diagnosis of exclusion.6 Its reported incidence 
between 0.3% and 21% is likely an underestimation 
of the true incidence.7,8 Opioid-related adverse events, 
including OIRD, are associated with increased length 
of stay (mean 5 additional days), readmission (15.8% 
vs 9.4% in patients without events), and cost (mean 
increase $10,000).9 The earliest warning of respiratory 
failure due to OIRD may be subtle changes in vital 
signs 6–8 hours before critical cardiac and respira-
tory decompensation ensues.10 Current general care 
floor monitoring often misses these early patterns or 
infers incorrect patterns, which are key to prevent-
ing catastrophic events. One investigation revealed 
that intermittent “spot check” monitoring every 4–6 
hours missed >90% episodes of prolonged hypoxemia 
on the general care floor.7 Similarly, in a closed claims 
analysis of the American Society of Anesthesiologists 
(ASA), a majority of the >357 OIRD events evolved 
rapidly and almost all could have been prevented 
with adequate monitoring and timely responses.11 It 
remains difficult to predict which general care floor 
patients are likely to decompensate when receiving 
analgesic opioids.12
The PRediction of Opioid-induced respiratory 
Depression In patients monitored by capnoGraphY 
(PRODIGY) trial investigated the incidence and risk 
factors associated with respiratory depression epi-
sodes in hospitalized patients receiving parenteral 
opioids and monitored by continuous capnography 
and oximetry. A respiratory depression risk prediction 
model was derived and validated, and the PRODIGY 
risk prediction tool was created.
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METHODS
Trial Design, Setting, and Participants
PRODIGY was a prospective trial conducted at 16 
clinical sites in the United States, Europe, and Asia 
(Supplemental Digital Content, Table 1, http://links.
lww.com/AA/D71), performed between April 2017 
and May 2018 (ClinicalTrials.gov: NCT02811302; regis-
tered Study Chair: F.J.O.; registration date: June 2016). 
The trial was registered before patient enrollment 
and conducted in compliance with the Declaration 
of Helsinki and applicable laws and regulations of 
participating countries, including institutional review 
board (IRB) or Research Ethics Committee approval. 
Eligible patients included adults (≥18, 20, and 21 
years in United States/Europe, Japan, and Singapore, 
respectively) able to provide written informed con-
sent, expected to receive parenteral opioid therapy 
on the general care floor, and able to wear continu-
ous monitoring equipment. Exclusion criteria were 
previously described (Supplemental Digital Content, 
Table 2, http://links.lww.com/AA/D71).1 Patients 
receiving opioids for nonsurgical pain were eligi-
ble for enrollment in the United States; all patients 
enrolled outside the United States were postsurgical. 
All adverse events were documented during continu-
ous monitoring and at 30-day follow-up. Respiratory 
depression episodes were classified as respiratory 
opioid-related adverse events only if standard of care 
monitoring indicated the patient was symptomatic of 
respiratory depression and intervention was required.
Procedures
Enrolled patients were monitored in adherence to each 
sites’ practice (vital sign checks every 4–8 hours), as 
well as continuous capnography and pulse oximetry 
monitoring, collected with a Capnostream 20p or 35 
portable bedside monitor (Medtronic, Boulder, CO). 
Continuous monitoring readings, alarms, and data 
were blinded to health care providers. Monitoring 
began after arrival on the general care floor and ini-
tiation of opioid therapy. Supplemental oxygen was 
allowed according to each sites’ clinical practice. A 
30-day follow-up phone call was conducted. Clinical 
sites were limited to maximum 20% of total enrollment.
Trial Objectives
The primary objective was to derive and validate a risk 
prediction tool for respiratory depression in patients 
receiving opioids, as detected by continuous pulse 
oximetry and capnography monitoring (primary end 
point). A respiratory depression episode was defined as 
any of the following: respiratory rate ≤5 breaths/min 
(bpm) for ≥3 minutes, oxygen saturation (Spo2) ≤85% 
for ≥3 minutes, end-tidal carbon dioxide (Etco2) ≤15 
or ≥60 mm Hg for ≥3 minutes, apnea episode lasting 
>30 seconds, or any respiratory opioid-related adverse 
event (Supplemental Digital Content, Table 3, http://
links.lww.com/AA/D71). The ≥3-minute threshold 
was used to minimize technical artifacts and transient 
threshold deviations. An independent clinical event 
committee reviewed Etco2, Spo2, respiratory rate, and 
heart rate tracings and decided on the presence of a 
respiratory episode and excluded artifacts on a case-by-
case basis using a predefined priority list (Supplemental 
Digital Content, Table 4, http://links.lww.com/AA/
D71). To evaluate respiratory depression relatedness 
to opioids, the committee had access to time records of 
opioid use on the general care floor but was blinded to 
all other patient medical and clinical history.
A priori defined secondary objectives included (1) 
comparing patients with and without ≥1 respiratory 
depression episode, with end points including adverse 
event incidence and health care resource utilization 
and (2) calculating the predictive value of Etco2, respi-
ratory rate, Spo2, and the Integrated Pulmonary Index 
(IPI) algorithm (determined by integrating Etco2, 
respiratory rate, Spo2, and heart rate signals into a 
single index using fuzzy logic)13 on the occurrence of 
respiratory depression for patients with ≥1 adjudicated 
respiratory depression episode, using sensitivity and 
specificity measures. Primary and secondary objec-
tives used a modified full analysis set, including only 
enrolled patients who started continuous monitoring 
and received parenteral opioid therapy, because some 
patients were enrolled based on “planned” opioid 
administration but did not receive opioids. Patients 
with only respiratory opioid-related adverse events 
occurring outside of continuous monitoring were 
excluded from the modified full analysis set.
Sample Size Calculations
A total of 1650 patients were calculated as adequate, 
based on expected model derivation with 12 predic-
tors, and a combined 12% reported incidence of respi-
ratory rate ≤8 bpm, Spo2 ≤85%, or Etco2 ≥60 mm Hg, 
each for ≥3 minutes.1,7,14 Enrollment was monitored 
and ended with 1495 patients due to high prevalence 
(44%) of adjudicated respiratory depression episodes; 
this was sufficient to power statistical analysis.
Statistical Analysis
Descriptive statistics were used to summarize patient 
characteristics, including mean, standard deviation, 
median, minimum, maximum, and interquartile 
range (IQR) for continuous variables, and counts and 
percentages for categorical variables. To compare 
patients with and without respiratory depression epi-
sodes, categorical variables were analyzed with the χ2 
test or the Fisher exact test, and continuous variable 
parameter comparisons were performed using t test 
or Wilcoxon test, as appropriate. Statistical tests used 
a 2-sided significance level of .05. All data analysis 
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used SAS v9.4 (SAS Institute Inc, Cary, NC). This man-
uscript adheres to the applicable STrengthening the 
Reporting of OBservational studies in Epidemiology 
(STROBE) guidelines.
Risk Prediction Derivation
Medical and clinical information were collected at 
patient enrollment or during continuous monitoring 
through medical chart review; adverse events, pro-
tocol deviations, and health care resource utilization 
information were collected during 30-day follow-up. 
Due to low prevalence of some risk factors and the 
unexpected high respiratory depression occurrence, 
the risk prediction tool was derived using all patients, 
instead of the derivation–validation split defined in 
the published trial protocol.1
Forty-six a priori defined variables collected during 
the trial were assessed, including 12 variables previ-
ously described as respiratory depression risk factors 
(Supplemental Digital Content, Table 5, http://links.
lww.com/AA/D71).3,15–19 Opioid naivety was defined 
as no history of opioid use as documented in available 
health records. Known or suspected sleep-disordered 
breathing included medical history of obstructive sleep 
apnea, the use of continuous positive airway pressure 
(CPAP), or confirmation of the Snoring, Tiredness, 
Observed apnea, blood Pressure (STOP) questions in 
the Snoring, Tiredness, Observed apnea, blood Pressure, 
Body mass index, Age, Neck circumference, and Gender 
(STOP-BANG) questionnaire. Variable collinearity was 
tested by Spearman rho, where a correlation coeffi-
cient >0.25 was used to identify covariables, and clini-
cal judgment used to determine covariable exclusion.20 
Covariables with prevalence <0.5% or >90% were also 
excluded, resulting in 31 variables (Supplemental Digital 
Content, Table 5, http://links.lww.com/AA/D71).
Bivariable odds ratios (ORs) and 95% confidence 
intervals (95% CIs) were estimated for all 31 variables. 
The multivariable logistic regression model used step-
wise selection with entry 0.25, stay criteria 0.15, and 
respiratory depression as the dependent variable. The 
model included all 2 × 2 interactions, with geography 
and effective length of monitoring (in quartiles, calcu-
lated as the total length of capnography monitoring 
excluding temporary gaps in monitoring) as random 
effects due to a correlation between monitoring length 
and respiratory depression occurrence. The main accu-
racy measure was the C-statistic equal to the area under 
the curve (AUC), derived from the mixed model. The 
final model was assessed using the calibration plot 
(predicted probability in deciles). Model prediction per-
formance was assessed using R2, Somers D, γ, τ-a, and 
Brier score. Internal model validation was assessed by 
bootstrapping with stepwise variable selection, estimat-
ing the optimism (500 random samples with replace-
ment from the original dataset), as recommended in 
the literature.21–23 The adjusted AUC was the differ-
ence between the AUC and optimism. Five-fold cross-
validation with 10 replicates, for a total of 50 iterations, 
was performed to confirm bootstrapping results. Cross-
validation was also performed using each trial site as a 
test set to confirm model performance across different 
hospital settings.24 The cross-validation performances 
were reported as the average AUC along with bias as 
the difference between the apparent and the test.
Risk Score Development
The PRODIGY risk score was calculated by multiply-
ing each β coefficient by 10, rounding to the nearest 
integer, and adding all integers. The resulting continu-
ous distribution of risk scores was stratified into 3 cat-
egories according to the risk level (tertiles), as planned 
before trial onset. The risk tool was assessed for accu-
racy using sensitivity and specificity, and respiratory 
depression incidence by risk levels was determined.
Missing Data
Because the clinical event committee adjudicated 
the respiratory depression episodes, there were no 
missing respiratory depression data. No imputation 
was used because missing covariable data were suf-
ficiently low (5.2%), given that a 10% cutoff is typical 
for large samples and no established cutoff defining 
an acceptable percentage of missing data exists.25
RESULTS
Patient Characteristics and Prevalence of 
Respiratory Depression
In total, 1495 patients were enrolled, with 114 patients 
excluded due to major protocol deviations; 1282 patients 
completed 30-day follow-up (Figure). The median 
effective monitoring time was 24 hours (IQR, 17–26) for 
1335 monitored patients (Figure; Supplemental Digital 
Content, Figure 1, http://links.lww.com/AA/D71). 
Median morphine milligram equivalents (MMEs) on 
the general care floor were 15 MMEs (IQR, 3–52) and 
20 MMEs (IQR, 5–60) for patients with ≥1 or without 
respiratory depression episodes, respectively. The clini-
cal event committee adjudicated 5768 potential respi-
ratory depression episodes in 1347 patients, including 
some patients who did not receive parenteral opioids 
(Supplemental Digital Content, Figure 2, http://links.
lww.com/AA/D71). Of all enrolled patients, 655 (44% 
of the full analysis set) were adjudicated as having at 
least 1 respiratory depression episode during the moni-
toring period, including 614 patients who received 
opioids and started continuous monitoring (46% of the 
modified full analysis set). Baseline characteristics var-
ied by location, with US sites enrolling younger patients 
with a higher body mass index (BMI, ≥35 kg/m2), 
larger neck circumference, higher ASA physical status, 
and higher STOP-BANG score, compared to patients 
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enrolled in Europe or Asia (Table 1). Of the 1185 patients 
who had ≥1 potential respiratory depression episode, 
731 patients (62%) received supplemental oxygen dur-
ing monitoring. A significantly higher percentage of 
patients enrolled in Asia were opioid naive (Table 1).
Univariable Predictors of Respiratory Depression
Significant univariable respiratory depression predic-
tors included age ≥70 to <80 or ≥80 years, male sex, 
BMI ≥20 to <25 or ≥35 kg/m2, opioid naivety, admin-
istration of ≥1 to <4 opioids, chronic heart failure, cor-
onary artery disease, hypertension, type II diabetes, 
kidney failure, and asthma (Table 2).
Respiratory Depression Risk Assessment Tool
The multivariable model for respiratory depression 
prediction was developed using 1266 patients (69 
missing data) and included 5 independent variables: 
age ≥60 to <70 years (OR, 2.24 [95% CI, 1.69–2.99]; P < 
.0001), ≥70 to <80 years (OR, 3.43 [95% CI, 2.41–4.89]; 
P < .0001), and ≥80 years (OR, 4.78 [95% CI, 2.33–9.80]; 
P < .0001); male sex (OR, 2.13 [95% CI, 1.65–2.74]; P 
< .0001); opioid naivety (OR, 1.34 [95% CI, 0.97–1.85]; 
P = .078); sleep disorders (known or suspected sleep 
disorders, including obstructive sleep apnea; OR, 1.61 
[95% CI, 1.10–2.38]; P = .018); and chronic heart failure 
(OR, 2.12 [95% CI, 0.95–4.72]; P = .067) (Table 3). This 
multivariable model had an AUC of 0.76 (95% CI, 0.73–
0.79) and a Hosmer–Lemeshow goodness-of-fit statis-
tic test with P = .831 (Supplemental Digital Content, 
Figure 3, http://links.lww.com/AA/D71). The 
adjusted AUC was 0.7406, considering the low opti-
mism (0.020). Bootstrapping selected the final model 
variables, including age, male sex, opioid naivety, 
sleep disorders, and chronic heart failure in 89%, 89%, 
24%, 31%, and 37% of 500 replicates, respectively 
(Supplemental Digital Content, Table 6, http://links.
lww.com/AA/D71). Complementary statistics com-
paring the fitted model with the null model included 
Brier score 0.19 (range for perfect model to null model, 
0–0.25), scaled Brier score 22% (range, 0–100), R2 0.22 
(range, 0–1), and adjusted R2 0.29 (range, 0–1).24 Rank 
correlation indexes measuring the ordinal association 
between 2 variables included Somers D 0.52, γ 0.53, 
and τ-a 0.26 (all on a −1 to 1 scale).24 Five-fold cross-
validation of the multivariable model resulted in an 
average AUC of 0.78 with bias equal to −0.02; simi-
lar results were observed using cross-validation by 
Figure. STROBE diagram detailing patient 
disposition throughout the trial, includ-
ing patients in the FAS and the MFAS. 
aIncluding 12-h nocturnal monitoring up 
to 2 consecutive nights (when possible). 
FAS indicates full analysis set; Incl/Excl, 
Inclusion/Exclusion; MFAS, modified full 
analysis set; STROBE, STrengthening the 
Reporting of OBservational studies in 
Epidemiology.
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Table 1.  Patient Demographics and Baseline Characteristics
Clinical Characteristics










Age (y)      
 Mean ± SD 54.9 ± 14.7 60.2 ± 12.5 62.7 ± 12.4 57.7 ± 14.2 <.001
 Median (IQR) 56.0 (44.0–65.0) 61.5 (53.0–69.0) 65.0 (57.0–70.0) 59.0 (49.0–68.0)  
Age (y) classes      
 <60 252/769 (32.8) 42/254 (16.5) 35/312 (11.2) 329/1335 (24.6) <.001
 ≥60 to <70 184/769 (23.9) 86/254 (33.9) 122/312 (39.1) 392/1335 (29.4)  
 ≥70 to <80 103/769 (13.4) 46/254 (18.1) 75/312 (24.0) 224/1335 (16.8)  
 ≥80 24/769 (3.1) 12/254 (4.7) 13/312 (4.2) 49/1335 (3.7)  
Sex (male) 287/769 (37.3) 126/254 (49.6) 157/312 (50.3) 570/1335 (42.7) <.001
BMI (kg/m2)      
 Mean ± SD 32.0 ± 9.2 27.8 ± 6.5 25.0 ± 4.5 29.6 ± 8.4 <.001
 Median (IQR) 30.1 (25.5–36.8) 26.7 (23.3–30.7) 24.5 (21.9–27.6) 27.8 (23.7–33.3)  
BMI (kg/m2)      
 <20 31/769 (4.0) 10/252 (4.0) 36/312 (11.5) 77/1333 (5.8) <.001
 ≥20 to <25 143/769 (18.6) 89/252 (35.3) 138/312 (44.2) 370/1333 (27.7)  
 ≥25 to <30 208/769 (27.0) 83/252 (32.9) 95/312 (30.4) 386/1333 (29.0)  
 ≥30 to <35 146/769 (19.0) 44/252 (17.5) 35/312 (11.2) 225/1333 (16.9)  
 ≥35 241/769 (31.3) 26/252 (10.3) 8/312 (2.6) 275/1333 (20.6)  
Race/ethnicity      
 American Indian or Alaska Native 3/769 (0.4) 0/254 (0) 1/312 (0.3) 4/1335 (0.3) <.001
 Asian 6/769 (0.8) 2/254 (0.8) 309/312 (99.0) 317/1335 (23.7)  
 Black or African American 157/769 (20.4) 1/254 (0.4) 0/312 (0) 158/1335 (11.8)  
 Hispanic or Latino 9/769 (1.2) 0/254 (0) 0/312 (0) 9/1335 (0.7)  
 Native Hawaiian or Other Pacific 1/769 (0.1) 0/254 (0) 0/312 (0) 1/1335 (0.1)  
 White 586/769 (76.2) 148/254 (58.3) 2/312 (0.6) 736/1335 (55.1)  
 Other 7/769 (0.9) 21/254 (8.3) 0/312 (0) 28/1335 (2.1)  
Current smoker 120/769 (15.6) 49/254 (19.3) 30/312 (9.6) 199/1335 (14.9) .004
Neck circumference (≥17 in M; ≥16 in F) 351/766 (45.8) 51/205 (24.9) 17/312 (5.4) 419/1283 (32.7) <.001
ASA physical status      
 I 4/744 (0.5) 35/254 (13.8) 75/312 (24.0) 114/1310 (8.7) <.001
 II 266/744 (35.8) 152/254 (59.8) 206/312 (66.0) 624/1310 (47.6)  
 III 448/744 (60.2) 66/254 (26.0) 31/312 (9.9) 545/1310 (41.6)  
 IV 26/744 (3.5) 1/254 (0.4) 0/312 (0.0) 27/1310 (2.1)  
Surgery demographics      
 Surgical patient 693/769 (90.1) 254/254 (100.0) 312/312 (100.0) 1259/1335 (94.3) <.001
 High-risk surgeryb 39/769 (5.1) 25/254 (9.8) 18/312 (5.8) 82/1335 (6.1) .022
 Open surgery 50/769 (6.5) 21/254 (8.3) 1/312 (0.3) 72/1335 (5.4) <.001
Length of surgery (h)      
 <2 290/769 (37.7) 53/254 (20.9) 87/312 (27.9) 430/1335 (32.2) <.001
 ≥2 to <4 311/769 (40.4) 125/254 (49.2) 119/312 (38.1) 555/1335 (41.6)  
 ≥4 168/769 (21.8) 76/254 (29.9) 106/312 (34.0) 350/1335 (26.2)  
Opioid demographics      
 Opioid epidural and IV route 32/769 (4.2) 8/254 (3.1) 93/312 (29.8) 133/1335 (10.0) <.001
 Opioid Naivec 551/769 (71.7) 224/254 (88.2) 301/312 (96.5) (80.6) 1076/1335 <.001
 Multiple opioids or concurrent CNS/ 
 sedating medication
722/769 (93.9) 220/254 (86.6) 306/312 (98.1) (93.5) 1248/1335 <.001
No. of distinct opioids      
 1 opioid 69/769 (9.0) 52/254 (20.5) 8/312 (2.6) 129/1335 (9.7) <.001
 Opioid number >1 to <4 451/769 (58.6) 152/254 (59.8) 277/312 (88.8) 880/1335 (65.9) <.001
 Opioid number ≥4 249/769 (32.4) 50/254 (19.7) 27/312 (8.7) 326/1335 (24.4)  
Cardiac disorders      
 Aortic aneurysm 8/769 (1.0) 2/254 (0.8) 0/312 (0) 10/1335 (0.7) .200
 Aortic valve disease 12/769 (1.6) 4/254 (1.6) 2/312 (0.6) 18/1335 (1.3) .487
 CHF 26/768 (3.4) 7/254 (2.8) 2/312 (0.6) 35/1334 (2.6) .023
 Coronary artery disease 55/767 (7.2) 10/254 (3.9) 16/312 (5.1) 81/1333 (6.1) .126
 Hypertension 366/769 (47.6) 96/254 (37.8) 150/312 (48.1) 612/1335 (45.8) .017
 Mitral valve disease 13/769 (1.7) 6/254 (2.4) 1/312 (0.3) 20/1335 (1.5) .110
 Myocardial infarction 21/768 (2.7) 9/254 (3.5) 4/312 (1.3) 34/1334 (2.5) .209
 Orthostatic hypotension 3/769 (0.4) 1/254 (0.4) 0/312 (0) 4/1335 (0.3) .644
 Pulmonary hypertension 8/769 (1.0) 1/254 (0.4) 0/312 (0) 9/1335 (0.7) .124
Hepatobiliary disorders      
 Liver failure 2/769 (0.3) 2/254 (0.8) 6/312 (1.9) 10/1335 (0.7) .011
Immune disorders      
 Sarcoidosis 3/769 (0.4) 0/254 (0) 0/312 (0) 3/1335 (0.2) .767
(Continued)
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trial site, where the average AUC was 0.83 and bias 
equaled −0.06.
The PRODIGY score equaled the sum of points for 
each predictor, and score distribution was divided into 
low-, intermediate-, and high-risk tertiles (Table  3). 
The average predicted probability for a PRODIGY 
score <8, ≥8 to <15, and ≥15 was 0.18–0.39, 0.33–0.65, 
and 0.50–0.89, respectively. Within the PRODIGY 
score high-risk group, 65% of patients had ≥1 respi-
ratory depression episode, compared to 42% and 24% 
of patients in the intermediate- and low-risk groups 
(Table 3). Patients with or without respiratory depres-
sion had significant separation in PRODIGY scores 
(P < .001) (Supplemental Digital Content, Figure 4, 
http://links.lww.com/AA/D71). High- and interme-
diate-risk scores had positive and negative predictive 
values equal to 0.65 and 0.54 and 0.66 and 0.76, respec-
tively. The high- and low-risk groups had OR of 6.07 
(95% CI, 4.44–8.30; P < .001) (Table 3), with high sensi-
tivity and specificity for the intermediate- (≥8 points) 
and high-risk (≥15 points) groups, respectively.
Predictive Value of Continuous Monitoring 
Parameters
The most common capnography and pulse oximetry 
alarms were for apnea, low respiratory rate, and low 
Etco2, with adjudicated respiratory depression epi-
sodes occurring in 596, 155, and 141 patients, respec-
tively (Table 4). No high Etco2 cases were observed. 
IPI <5 (1–10 scale with lower numbers indicating 
worse status) and apnea had the highest sensitivity 
(97.16; 95% CI, 95.84–98.16 and 95.01; 95% CI, 93.35–
96.35, respectively), and low Spo2 with low Etco2 had 
the highest specificity (98.75; 95% CI, 98.36–99.06) in 
detecting respiratory depression episodes (Table 4).
Adverse Events and Health Care Resource Utili-
zation
A total of 313 patients experienced ≥1 adverse event, 
including 22 opioid-related adverse events in 18 
patients (Supplemental Digital Content, Table 7, 
http://links.lww.com/AA/D71). Ten opioid-related 
adverse events were detected by capnography 
Infections      
 Multiple organ dysfunction syndrome 2/769 (0.3) 0/254 (0) 0/312 (0) 2/1335 (0.1) 1.000
 Sepsis 15/769 (2.0) 2/254 (0.8) 0/312 (0) 17/1335 (1.3) .014
Metabolism and nutrition disorders      
 Diabetes—type I 18/769 (2.3) 1/254 (0.4) 0/312 (0) 19/1335 (1.4) .002
 Diabetes—type II 124/769 (16.1) 37/254 (14.6) 53/312 (17) 214/1335 (16.0) .733
Musculoskeletal and connective tissue disorders      
 Muscular dystrophy 2/769 (0.3) 0/254 (0) 0/312 (0) 2/1335 (0.1) 1.000
 Amyotrophic lateral sclerosis 0/769 (0) 0/254 (0) 0/312 (0) 0/1335 (0) 1.000
 Renal and urinary disorders      
 Kidney failure 29/769 (3.8) 14/254 (5.5) 11/312 (3.5) 54/1335 (4.0) .412
Respiratory, thoracic, and mediastinal disorders      
 Acute bronchitis 13/769 (1.7) 0/254 (0) 0/312 (0) 13/1335 (1.0) .006
 Asthma 121/769 (15.7) 18/254 (7.1) 23/312 (7.4) 162/1335 (12.1) <.001
 Chronic bronchitis 9/769 (1.2) 3/254 (1.2) 1/312 (0.3) 13/1335 (1.0) .402
 Chronic obstructive pulmonary disease 60/769 (7.8) 12/254 (4.7) 7/312 (2.2) 79/1335 (5.9) .001
 Chronic restrictive lung disease 3/769 (0.4) 0/254 (0) 0/312 (0) 3/1335 (0.2) .767
 Cystic fibrosis 0/769 (0) 0/254 (0) 0/312 (0) 0/1335 (0) .767
 Emphysema 5/769 (0.7) 0/254 (0) 0/312 (0) 5/1335 (0.4) .234
 Pneumonia 15/769 (2.0) 6/254 (2.4) 9/312 (2.9) 30/1335 (2.2) .638
 Pulmonary fibrosis 2/769 (0.3) 0/254 (0) 0/312 (0) 2/1335 (0.1) 1.000
Sleep disordersd 127/760 (16.7) 13/195 (6.7) 7/312 (2.2) 147/1267 (11.6) <.001
Vascular disorders      
 Cerebral aneurysm 8/769 (1.0) 0/254 (0) 0/312 (0) 8/1335 (0.6) .066
 Peripheral vascular disease 18/769 (2.3) 8/254 (3.1) 2/312 (0.6) 28/1335 (2.1) .090
 Stroke 14/768 (1.8) 5/254 (2.0) 5/312 (1.6) 24/1334 (1.8) .946
 Transient ischemic attack 11/768 (1.4) 4/254 (1.6) 2/312 (0.6) 17/1334 (1.3) .561
STOP-BANG score class      
 Low risk (0–2) 343/756 (45.4) 102/192 (53.1) 180/312 (57.5) 625/1260 (49.6) <.001
 Intermediate risk (3–4) 265/756 (35.1) 60/192 (31.3) 114/312 (36.5) 439/1260 (34.8)  
 High risk (5–8) 148/756 (19.6) 30/192 (15.6) 18/312 (5.8) 196/1260 (15.6)  
Medical patients were enrolled at US sites only, and medical history was collected from chart review.
Abbreviations: ASA, American Society of Anesthesiologists; BMI, body mass index; CHF, chronic heart failure; CNS, central nervous system; CPAP, continuous 
positive airway pressure; ESC/ESA, European Society of Cardiology/European Society of Anaesthesiology; F, female; IQR, interquartile range; IV, intravenous; M, 
male; SD, standard deviation; STOP, Snoring, Tiredness, Observed apnea, blood Pressure; STOP-BANG, Snoring, Tiredness, Observed apnea, blood Pressure, Body 
mass index, Age, Neck circumference, and Gender.
aP values are not adjusted for multiple comparisons.
bHigh-risk surgery was defined using the revised ESC/ESA guidelines on noncardiac surgery.
cOpioid naive was defined as no use of any opioids in patient medication history.
dSleep disorders included medical history of obstructive sleep apnea, use of CPAP, or confirmation of the STOP questions in the STOP-BANG questionnaire.
Table 1.  Continued
Clinical Characteristics
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and pulse oximetry monitoring; 11 occurred in 
the absence of continuous monitoring and were 
excluded during model derivation (Supplemental 
Digital Content, Table 8, http://links.lww.com/AA/
D71). Of patients with opioid-related adverse events, 
9, 6, and 3 were high-, intermediate-, and low-risk 
on the PRODIGY score, respectively. Patients with 
≥1 respiratory depression episode (N = 655) were 
more likely to experience an adverse event that 
required action, with a relative risk of 1.36 (95% CI, 
1.01–1.78; P = .040) for adverse events requiring pro-
longed hospitalization and 2.46 (95% CI, 1.73–3.50; P 
< .001) for adverse events requiring rescue, includ-
ing rapid response team activation, versus patients 
Table 2.  Univariable Predictors of Respiratory Depression
Clinical Characteristics
Patients With ≥1  
Respiratory Depression  
Episode (n = 614), n/N (%)
Patients Without  
Respiratory Depression 
(n = 721), n/N (%) OR (95% CI)
Significance  
(P)
Age (y)     
 <60 73/614 (11.9) 256/721 (35.5) … …
 ≥60 to <70 213/614 (34.7) 179/721 (24.8) 2.47 (1.91–3.19) .585
 ≥70 to <80 149/614 (24.3) 75/721 (10.4) 4.12 (2.99–5.68) <.001
 ≥80 34/614 (5.5) 15/721 (2.1) 4.70 (2.51–8.81) .014
Sex (male) 327/614 (53.3) 243/721 (33.7) 2.24 (1.80–2.80) <.001
BMI (kg/m2)     
 <20 34/612 (5.6) 43/721 (6.0) … …
 ≥20 to <25 188/612 (30.7) 182/721 (25.2) 1.31 (0.80–2.14) .029
 ≥25 to <30 186/612 (30.4) 200/721 (27.7) 1.18 (0.72–1.92) .236
 ≥30 to <35 112/612 (18.3) 113/721 (15.7) 1.25 (0.75–2.11) .130
 ≥35 92/612 (15.0) 183/721 (25.4) 0.64 (0.38–1.06) <.001
Current smoker 90/614 (14.7) 109/721 (15.1) 0.96 (0.71–1.31) .814
Sleep disorders 75/575 (13.0) 72/692 (10.4) 1.29 (0.92–1.82) .145
Cardiac disorders     
 Aortic aneurysm 8/614 (1.3) 2/721 (0.3) 4.75 (1.00–22.43) .049
 Aortic valve disease 12/614 (2.0) 6/721 (0.8) 2.38 (0.89–6.37) .085
 CHF 24/613 (3.9) 11/721 (1.5) 2.63 (1.28–5.41) .009
 Coronary artery disease 47/612 (7.7) 34/721 (4.7) 1.68 (1.07–2.65) .025
 Hypertension 321/614 (52.3) 291/721 (40.4) 1.62 (1.30–2.01) <.001
 Mitral valve disease 9/614 (1.5) 11/721 (1.5) 0.96 (0.40–2.33) .929
 Myocardial infarction 20/613 (3.3) 14/721 (1.9) 1.70 (0.85–3.40) .132
 Pulmonary hypertension 5/614 (0.8) 4/721 (0.6) 1.47 (0.39–5.51) .565
Hepatobiliary disorders     
 Liver failure 6/614 (1.0) 4/721 (0.6) 1.77 (0.50–6.30) .379
Infections     
 Sepsis 9/614 (1.5) 8/721 (1.1) 1.33 (0.51–3.46) .562
Metabolism and nutrition disorders     
 Diabetes—type I 9/614 (1.5) 10/721 (1.4) 1.06 (0.43–2.62) .903
 Diabetes—type II 112/614 (18.2) 102/721 (14.1) 1.35 (1.01–1.81) .043
Renal and urinary disorders     
 Kidney failure 33/614 (5.4) 21/721 (2.9) 1.89 (1.08–3.31) .025
Respiratory, thoracic, and mediastinal disorders     
 Acute bronchitis 4/614 (0.7) 9/721 (1.2) 0.52 (0.16–1.69) .277
 Asthma 55/614 (9.0) 107/721 (14.8) 0.56 (0.40–0.80) .001
 Chronic bronchitis 7/614 (1.1) 6/721 (0.8) 1.38 (0.46–4.12) .568
 Chronic obstructive pulmonary disease 43/614 (7.0) 36/721 (5.0) 1.43 (0.91–2.26) .122
Vascular disorders     
 Cerebral aneurysm 5/614 (0.8) 3/721 (0.4) 1.96 (0.47–8.26) .356
 Peripheral vascular disease 16/614 (2.6) 12/721 (1.7) 1.58 (0.74–3.37) .235
 Stroke 13/613 (2.1) 11/721 (1.5) 1.40 (0.62–3.14) .417
 Transient ischemic attack 10/613 (1.6) 7/721 (1.0) 1.69 (0.64–4.47) .290
Surgery information     
 High-risk surgery 41/614 (6.7) 41/721 (5.7) 1.19 (0.76–1.86) .453
 Open surgery 34/614 (5.5) 38/721 (5.3) 1.05 (0.65–1.70) .829
Length of surgery (h)     
 <2 184/614 (30.0) 246/721 (34.1) … …
 ≥2 to <4 264/614 (43.0) 291/721 (40.4) 1.21 (0.94–1.56) .374
 ≥4 166/614 (27.0) 184/721 (25.5) 1.21 (0.91–1.60) .467
No. of distinct opioids     
 Opioid naive 520/614 (84.7) 556/721 (77.1) 1.64 (1.24–2.17) <.001
 One opioid 55/614 (9.0) 74/721 (10.3) … …
 Opioid number ≥1 to <4 431/614 (70.2) 449/721 (62.3) 1.29 (0.89–1.88) .009
 Opioid number ≥4 128/614 (20.8) 198/721 (27.5) 0.87 (0.58–1.32) .071
Abbreviations: BMI, body mass index; CHF, chronic heart failure; CI, confidence interval; OR, odds ratio.
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without respiratory depression (Supplemental 
Digital Content, Table 9, http://links.lww.com/
AA/D71). Of 46 adverse events with rescue action, 
30 occurred in patients with ≥1 respiratory depres-
sion episode. Readmission (≤30 days) did not differ 
significantly between patients with or without respi-
ratory depression. Mean hospital length of stay was 
3 days longer in patients with ≥1 respiratory depres-
sion episode (10.5 ± 10.8 vs 7.7 ± 7.8 days; P < .0001; 
Supplemental Digital Content, Table 10, http://
links.lww.com/AA/D71).
DISCUSSION
Despite its commonality on the general care floor, 
predicting respiratory depression remains challeng-
ing.12 Multiple prediction scores have been developed 
using postoperative pulmonary complications.26,27 
The PRODIGY trial is novel because it derived a 
respiratory depression risk prediction tool using con-
tinuously monitored oximetry and capnography data, 
which were prospectively collected and evaluated 
using independent expert waveform verification.
The PRODIGY risk prediction tool performed simi-
larly when validated by bootstrapping and by cross-
validation (adjusted AUC, 0.74 and 0.76, respectively), 
confirming that the model performs well overall and 
across 16 individual trial sites. Prediction models for 
postoperative pulmonary complications have reported 
adjusted AUCs between 0.72 and 0.82,15,28–30 with one 
model reaching 0.88.26 The PRODIGY risk score com-
pares well and is distinct from other prediction mod-
els, which are derived using intermittent vital signs or 
continuous pulse oximetry alone. The PRODIGY score 
identified 74% of patients with respiratory depression, 
with significant separation among low-, intermediate-, 
and high-risk groups. The 5 PRODIGY score variables 
are simple to assess, making the risk prediction tool 
easy to implement. Increasing age >60 years conferred 
the highest risk for respiratory depression. Age is a 
feature of other respiratory depression risk predic-
tion models,26,27,31 and age-related changes in respira-
tory physiology and altered opioid pharmacokinetics 
could contribute to this observation.32
Postoperative hypoxemia (low Spo2) has been 
reported in 21% of postsurgical patients.7 While the 
PRODIGY trial saw a higher overall incidence of 
respiratory depression (46%), this could be attributed 
to the use of multiparameter continuous monitor-
ing (Etco2, Spo2, respiratory rate, and heart rate). A 
majority of our patients used supplemental oxygen, 
translating into fewer (8%) hypoxemia episodes and 
more capnography-detected apneic and hypoven-
tilation episodes.33 As expected, the combination of 
hypoventilation and hypoxemia was most specific 
for respiratory depression. In contrast to continuous 
oximetry and capnography monitoring, intermit-
tent oximetry alone substantially underestimates 
respiratory depression incidence, missing >90% of 
Table 3.  Multivariable Model Prediction of Respiratory Depression, PRODIGY Scoring System, and Utilization
Multivariable Model Predictors  Points if Clinical 
Characteristic = “Yes”Clinical Characteristic Estimate Standard Error OR (95% CI) Pr > |t|
Age (y)      
 <60 Reference … … … 0
 ≥60 to <70 0.8077 0.1458 2.243 (1.685–2.985) <0.0001 8
 ≥70 to <80 1.2323 0.1805 3.429 (2.407–4.886) <0.0001 12
 ≥80 1.5647 0.3657 4.781 (2.333–9.798) <0.0001 16
Sex (M) 0.7550 0.1284 2.128 (1.654–2.737) <0.0001 8
Opioid naive 0.2912 0.1652 1.338 (0.968–1.850) 0.0782 3
Sleep disorders 0.4755 0.1998 1.609 (1.087–2.381) 0.0175 5
Chronic heart failure 0.7494 0.4085 2.116 (0.949–4.715) 0.0668 7
     “Sum = PRODIGY Score”
PRODIGY Score Distribution  
 Low Risk Intermediate Risk High Risk P  
PRODIGY score <8 points ≥8 and <15 points ≥15 points   
% Pts with respiratory depression in  
risk category (n Pts in risk category 
with respiratory depression/n Pts in 
risk category)
24% (83/351) 42% (192/457) 65% (299/458) <.0001  
Sensitivity (95% CI) … 0.86 (0.82–0.88) 0.52 (0.48–0.56)   
Specificity (95% CI) … 0.39 (0.35–0.42) 0.77 (0.74–0.80)   
PPV (95% CI) … 0.54 (0.50–0.57) 0.65 (0.61–0.70)   
NPV (95% CI) … 0.76 (0.72–0.81) 0.66 (0.63–0.69)   
OR (95% CI; P) ORIL =2.34 
(1.72–3.19; P < .001)
ORHL = 6.07  
(4.44–8.30; P < .001)
ORHI =2.6  
(1.99–3.39; P < .001)
   
Abbreviations: CI, confidence interval; M, male; NPV, negative predictive value; OR, odds ratio; ORHI, odds ratio, high- versus intermediate-risk groups; ORHL, odds 
ratio, high- versus low-risk groups; ORIL, odds ratio, intermediate- versus low-risk groups; PPV, positive predictive value; PRODIGY, PRediction of Opioid-induced 
respiratory Depression In patients monitored by capnoGraphY; Pts, patients.
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hypoxemia episodes lasting >1 hour.7,33,34 PRODIGY 
observed no instances of high Etco2, which manifests 
during slowly developing respiratory depression. In 
cases of rapid cessation of breathing, as is typical in 
patients with sleep-disordered breathing, Etco2 lev-
els tend to be low.35 This suggests that most OIRD 
developed rapidly without time for Etco2 accumu-
lation and is consistent with evidence that patients 
can develop respiratory arrest shortly after a nursing 
visit.11
Improved OIRD detection on the general care 
floor has important clinical implications, as shown 
by a reduction of rapid response calls when using 
unblinded continuous capnography.36 In this trial, 
rescue, including rapid response team activation, and 
hospitalization prolongation due to an adverse event 
were 2.5 and 1.4 times higher, respectively, for patients 
with respiratory depression. Consistent with previous 
reports, patients with ≥1 respiratory depression epi-
sode experienced a 3-day longer hospital stay,9 equat-
ing to an economic burden of ≈$2000/d of inpatient 
hospitalization and potential costs due to complica-
tions and escalation of care.37,38
Overall, the number of opioid-induced respira-
tory complications requiring rescue was low. Ten 
patients required rescue treatment during continuous 
monitoring, and 11 patients needed rescue outside 
of continuous monitoring. This frequency of res-
cue treatment is consistent with recent studies using 
postoperative naloxone administration to define 
OIRD18,39,40 and supports the hypothesis that OIRD 
requiring rescue action occurs in ≈1 of 1000 general 
care floor patients.18,39 Combined, the potential sever-
ity of respiratory complications (death, anoxic brain 
injury) and the lack of OIRD detection by current 
monitoring practices highlight the need for risk pre-
diction and adequate monitoring. Implementation of 
the PRODIGY score to determine the need for con-
tinuous monitoring may be a first step to reduce the 
consequences of respiratory compromise.
One strength of the PRODIGY trial design was 
inclusion of blinded, continuously monitored oxim-
etry and capnography data and respiratory depres-
sion episode adjudication using an independent 
clinical event committee, allowing us to observe the 
true burden of respiratory depression. Furthermore, 
Table 4.  Predictive Value of Etco2, Respiratory Rate, Spo2, Apnea, and IPI in Predicting Respiratory Opioid-
Related Adverse Events
Parameter
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Of the 1185 patients with device episodes, 731 patients received supplemental oxygen during monitoring, with 203 receiving supplemental oxygen at baseline.
Abbreviations: bpm, breaths/min; CI, confidence interval; Etco2, end-tidal carbon dioxide; IPI, Integrated Pulmonary Index; Pts, patients; Spo2, oxygen saturation.
aRespiratory depression is defined as respiratory rate ≤5 bpm, Spo2 ≤85%, or Etco2 ≤15 or ≥60 mm Hg for ≥3 minutes; apnea episode lasting >30 seconds; or 
any respiratory opioid-related adverse event.
bPatients with potential opioid-related adverse events only were excluded due to the lack of device monitoring.
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we included surgical and medical patients transferred 
to a range of general care floors in Europe, the United 
States, and Asia, making our findings generalizable. 
Although it remains to be seen if universal continuous 
monitoring will lead to a survival benefit for general 
care floor patients, our data suggest that screening 
with the easy-to-use PRODIGY score and the use of 
continuous monitoring at least in patients with high 
respiratory depression risk may prevent harm to 
the individual patient. For example, a 72-year-old 
male patient with chronic heart failure who is opi-
oid naive is at a >2-fold risk of respiratory depres-
sion (PRODIGY score = 30; high risk) compared to a 
67-year-old female patient with diabetes and chronic 
kidney disease who has previously received opioids 
(PRODIGY score = 8; intermediate risk) after a similar 
surgical procedure, when both receive opioids on the 
general care floor. Along with judicious use of opi-
oids, this high-risk patient may benefit from continu-
ous capnography and oximetry monitoring.
This work has some limitations. To evaluate OIRD 
episodes, the clinical event committee required access 
to opioid usage data, which could have influenced 
episode adjudication. Thus, opioid naivety, but not 
opioid doses and routes, was included in the model. 
Second, although only one-fifth of all adjudicated 
respiratory depression episodes were denoted as 
having ≥1 artifact, capnography data were subject to 
artifact and patient compliance. Finally, the trial was 
internally validated but lacks external validation on 
an independent cohort, primarily due to the nonavail-
ability of a robust, continuously monitored patient 
dataset from the general care floor. Future studies are 
needed to validate the risk prediction tool.
Parenteral opioid use alone or in combination with 
sedatives is strongly associated with cardiopulmonary 
arrests on the general care floor.38 While judicious use 
of these interventions is important, continuous moni-
toring for patients receiving opioids is also deficient. 
A high incidence of respiratory depression episodes 
was detected using continuous monitoring and these 
may contribute to significant morbidity as seen by 
the higher incidence of rapid response activation and 
prolonged hospitalization. In the absence of interven-
tional trials testing continuous monitoring and inpa-
tient mortality, results from PRODIGY provide a tool 
for respiratory depression risk assessment and suggest 
that continuous monitoring with capnography and 
oximetry of patients identified as high risk for respira-
tory depression may improve their safety when paren-
teral opioid analgesia cannot be avoided. E
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